Section
Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.
Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.
Single-cell RNA sequencing suggests that childhood poverty exposure is associated with steroid-resistance signatures in leukemic blasts and adverse immune remodeling at diagnosis in standard-risk B-ALL.
In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.
A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.
A single-center validation study suggests the CTCL-PRO-20 may provide a reliable, disease-specific measure of quality of life in patients with cutaneous T-cell lymphoma.
Anti-CD117 CAR T-cell therapy demonstrated potent elimination of malignant mast cells in preclinical models of advanced systemic mastocytosis, offering a potential new treatment approach for this aggressive disorder.
A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.
A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast can
這項涵蓋19國55個ICU的2003名患者研究發現，急性白血病危重患者總體ICU死亡率為45%，需機械通氣者達66%。年齡>65歲、AML診斷、化療期間入院等因素顯著增加死亡風險，但隨時間推移生存率有所改善。
This review synthesizes clinical evidence on busulfan pharmacokinetics, highlighting the critical role of TDM, the impact of body weight normalization, and significant drug interactions with deferasirox.
A French study reveals African ancestry significantly increases relapse risk in iTTP patients treated with rituximab. Key risk factors include male sex and prior relapses, with implications for personalized monitoring strategies.
A multicenter retrospective study suggests that MDS with isolated del(5q) and TP53 multihit alterations has substantially better survival than other low-blast TP53-multihit MDS, challenging how this subgroup should be classified.
A large multicenter study links specific bone marrow immune cell patterns to infection risk in multiple myeloma and proposes a clinically relevant immune score that may support minimally invasive monitoring.
Study reveals inadequate hemoglobin improvement at 20-24 weeks after iron therapy increases stillbirth and preterm birth risks in moderate iron deficiency anemia pregnancies, highlighting need for early intervention.
A prospective multicenter study reports excellent survival, no graft failure, and very low GVHD with a thiotepa-based reduced-intensity matched sibling transplant platform for severe sickle cell disease.
A 2026 single-center retrospective study suggests alpha-1-antitrypsin may offer favorable safety and encouraging activity in heavily pretreated gastrointestinal acute GVHD, though detailed outcome data and external validation remain essenti
A large meta-analysis shows MRD strongly predicts outcomes for individual patients with CLL, but is an inconsistent trial-level surrogate for progression-free survival, particularly with BTK inhibitor and venetoclax-based regimens.
In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell tra
This cohort study highlights the underutilization of timely palliative care in adolescent and young adult cancer patients opting for MAID, with significant symptom burden and complex psychosocial factors influencing end-of-life decisions.
